[ET Net News Agency, 24 November 2021] BeiGene, Ltd. (06160) said the European
Commission (EC) approved BRUKINSA (zanubrutinib) for the treatment of adult patients with
Waldenstrom's macroglobulinemia (WM) who have received at least one prior therapy or for
the first-line treatment of patients unsuitable for chemo-immunotherapy.
The approval is applicable to all 27 European Union (EU) member states, plus Iceland and
Norway. BeiGene is working to make this new treatment option available to WM patients in
the EU as quickly as possible. (RC)